| Literature DB >> 31330856 |
Laura Buzón-Durán1, Jesús Martín-Gil1, Eduardo Pérez-Lebeña1, David Ruano-Rosa2, José L Revuelta3, José Casanova-Gascón4, M Carmen Ramos-Sánchez5, Pablo Martín-Ramos6.
Abstract
Grapevine trunk diseases (GTDs) are a major threat to the wine and grape industry. The aim of the study was to investigate the antifungal activity against Neofusicoccum parvum, Diplodia seriata, and Botryosphaeria dothidea of ε-polylysine, chitosan oligomers, their conjugates, Streptomyces rochei and S. lavendofoliae culture filtrates, and their binary mixtures with chitosan oligomers. In vitro mycelial growth inhibition tests suggest that the efficacy of these treatments, in particular those based on ε-polylysine and ε-polylysine:chitosan oligomers 1:1 w/w conjugate, against the three Botryosphaeriaceae species would be comparable to or higher than that of conventional synthetic fungicides. In the case of ε-polylysine, EC90 values as low as 227, 26.9, and 22.5 µg·mL-1 were obtained for N. parvum, D. seriata, and B. dothidea, respectively. Although the efficacy of the conjugate was slightly lower, with EC90 values of 507.5, 580.2, and 497.4 µg·mL-1, respectively, it may represent a more cost-effective option to the utilization of pure ε-polylysine. The proposed treatments may offer a viable and sustainable alternative for controlling GTDs.Entities:
Keywords: Botryosphaeria dothidea; Diplodia seriata; Neofusicoccum parvum; conjugate complexes; grapevine trunk diseases
Year: 2019 PMID: 31330856 PMCID: PMC6783921 DOI: 10.3390/antibiotics8030099
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Comparison of the attenuated total reflection (ATR)-Fourier-Transform Infrared (FTIR) spectra of ε-polylysine:chitosan oligomers conjugates prepared with different ε-polylysine:chitosan oligomers mass ratios. Only the fingerprint region is shown.
Figure 2N. parvum mycelial growth inhibition assays for: (a) chitosan oligomers; (b) ε-polylysine; (c) S. rochei secondary metabolites; (d) S. lavendofoliae secondary metabolites; (e) ε-polylysine:chitosan (1:1 w/w) conjugates; (f) S. rochei secondary metabolites + chitosan oligomers (1:1 w/w); and (g) S. lavendofoliae secondary metabolites + chitosan oligomers (1:1 w/w). The concentration of the treatments decreases from top to bottom (doses for each treatment are indicated in Table 3). The petri dish in the bottom right corner shows the PDA control. Only one replicate per each treatment and dose is shown.
Figure 3Radial growth values of (a) N. parvum; (b) D. seriata; and (c) B. dothidea in the presence of the different treatments under study at different concentrations (in µg·mL−1). COS, EPL, MR, ML and C stand for chitosan oligomers, ε-polylysine, S. rochei secondary metabolites, S. lavendofoliae secondary metabolites and control, respectively. For MR and ML only one column is shown, since no inhibition was detected at any concentration in the 250–1500 µg·mL−1 range. Concentrations labelled with the same uppercase letters are not significantly different at p < 0.05 by Tukey’s test. All values are presented as the average of three repetitions. Error bars represent the standard deviation across three replicates.
Effective concentrations that inhibited mycelial growth by 50% and 90% (EC50 and EC90, respectively).
| Pathogen | Concentration (µg·mL−1) | Treatment | ||||
|---|---|---|---|---|---|---|
| COS | EPL | EPL:COS | MR + COS | ML + COS | ||
|
| EC50 | 60.7 | 16.0 | 11.2 | 67.2 | 46.7 |
| EC90 | 1270.0 | 227.0 | 507.5 | 2074.2 | 1101.7 | |
|
| EC50 | 94.3 | 0.3 | 11.6 | 45.1 | 30.7 |
| EC90 | 1120.7 | 26.9 | 580.2 | 906.9 | 498.2 | |
|
| EC50 | 1.8 | 0.4 | 4.2 | 15.8 | 10.7 |
| EC90 | 689.5 | 22.5 | 497.4 | 1019.0 | 490.3 | |
Concentration values and associated inhibition rates, or EC50 values, reported in the literature for other active compounds against the three Botryosphaeriaceae species under study.
| Fungicide | Fungal Species | Concentration (µg·mL−1) | Inhibition rate (%) | EC50(µg·mL−1) | Ref. |
|---|---|---|---|---|---|
| Tebuconazole |
| 90 | [ | ||
|
| 150 | ||||
| Pyraclostrobin |
| 100 | |||
|
| 250 | ||||
| Carbendazim, tebuconazole, iprodione, fludioxonil, fluazinam, flusilazole, penconazole, procymidone, myclobutanil, pyraclostrobin |
| 360–440 * | [ | ||
|
| 530–620 * | ||||
|
| 450 * | ||||
| Carbendazim |
| 40 | [ | ||
| Tebuconazole | 130 | ||||
| Iprodione | 750 | ||||
| Tecobunazole |
| 300 | [ | ||
| Fe NPs (FeNPs + neem leaf extract) |
| 100 (FeNPs / FeNPs+neem 1:1) | 79/80.3 | [ | |
|
| 83/82.5 | ||||
| AgNPs |
| 40 | 84 | [ | |
| AgNPs | 30 | 81 | [ | ||
| Lemon essential oil (limonene, neral, β-pinene, and γ-terpinene) in DMSO |
| 2500 | 48.1 | [ | |
| Chitosan oligosaccharin (mol. wt. <3 kDa) | 1.56 | [ | |||
| Chitosan oligosaccharides |
| 1000 | 100 | [ | |
| Vanillin | 1000 | 89.8 | |||
| Garlic extract | 40000 | 75.3 |
* Data pooled across fungicides to provide mean EC50 values for isolate sensitivity in the original study.
Concentrations assayed for each of the treatments in the mycelial growth inhibition tests. COS, PL, MR and ML stand for chitosan oligomers, ε-polylysine, S. rochei secondary metabolites, and S. lavendofoliae secondary metabolites, respectively.
| Treatment | Concentrations Assayed in the Mycelial Growth Inhibition Tests (μg∙mL−1) |
|---|---|
| COS | 62.5, 125, 250, 500, 750, 1000, 1250, 1500 |
| EPL | 25, 50, 100, 200, 400, 600, 800, 1000 |
| MR | 250, 500, 750, 1000, 1250, 1500 |
| ML | 250, 500, 750, 1000, 1250, 1500 |
| EPL:COS | 250, 500, 750, 1000, 1250, 1500 |
| MR+COS | 200, 400, 600, 800, 1000, 1200 |
| ML+COS | 200, 400, 600, 800, 1000, 1200 |